📰 Current Management News
Page 3 - Current Management News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Current Management. Real-time updates on events, politics, business and more.
June 23, 2022
/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global biopharmaceutical company, today announced two scientific posters to be presented on the disease...
January 3, 2022
Expert Opinion on Biological Treatment of Chronic Rhinosinusitis with Nasal Polyps in the Gulf Region
November 22, 2021
/PRNewswire/ - QYOU Media Inc.,(TSXV: QYOU) (OTCQB: QYOUF) announced today that its USA based award-winning influencer marketing business unit has named Glenn...
November 22, 2021
/PRNewswire/ - QYOU Media Inc.,(TSXV: QYOU) (OTCQB: QYOUF) announced today that its USA based award-winning influencer marketing business unit has named Glenn...
July 23, 2021
据悉，该基金的投资目标如下：该基金通过积极主动的资产配置与严谨的风险管理，在严格控制风险的前提下，积极把握证券市场的投资机会，追求资产的保值增值。 该基金的风险收益特征如下：该基金为混合型基金，预期收益和预期风险高于货币市场基金、债券型基金，但低于股票型基金。该基金将投资港股通标的股票，需承担港股通机制下因投资环境、投资标的...
July 21, 2021
资料显示，戴晓云曾任海证期货有限公司副总经理、上海证券有限责任公司运营中心副总经理、上投摩根基金管理有限公司数字化运营及拓展部总监等职，2016年7月加入万家基金，现任公司总经理助理、网络金融部总监，兼任万家财富基金销售(天津)有限公司董事长。 Choice数据显示，成立于2002年8月的万家基金，截至目前，资产规模(全部)2167.60亿元，排名29/166;资产规...
July 14, 2021
Guatemala-Stadt. Guatemaltek:innen gehen erneut gegen den Präsidenten Alejandro Giammattei auf die Straße und fordern seinen Rücktritt. Am vergangenen Samstag gab es Demonstrationen in der Hauptstadt, die Gerechtigkeit für die Ermordung des politischen Aktivisten Frank Ramazzini forderten und den aktuellen Umgang der Regierung mit der Corona-Pandemie kritisierten. Viele Bürger:innen demonstrierten in jüngster Vergangenheit regelmäßig gegen die Politik von Giammattei. Insbesondere mangel...
May 19, 2021
no ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s notable to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.” In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combinatio...